| 摘要 |
PROBLEM TO BE SOLVED: To provide a compound modulating activity at CXC-chemokine receptors. SOLUTION: The present invention relates to four distinct crystalline polymorphs of a monohydrate of a compound A having the following chemical structure (A). These four polymorphic forms, herein referred to as forms I, II, III and IV, are active as a CXC-chemokine receptor ligand. The invention is further directed to formulations, methods of treatment, and processes of synthesis of these polymorphic forms. Chemokine-mediated diseases treatable by these polymorphic forms include pain, acute inflammation, chronic inflammation, rheumatoid arthritis, psoriasis, atopic dermatitis, asthma, COPD, adult respiratory disease, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram-negative bacterial sepsis, toxic shock syndrome, stroke, ischemia, reperfusion injury, renal reperfusion injury, glomerulonephritis, thrombosis, Alzheimer's disease, and the like. COPYRIGHT: (C)2011,JPO&INPIT
|
